{
    "clinical_study": {
        "@rank": "157968", 
        "arm_group": [
            {
                "arm_group_label": "ExAblate Transcranial MRgFUS", 
                "arm_group_type": "Experimental", 
                "description": "ExAblate Transcranial MR guided Focused Ultrasound"
            }, 
            {
                "arm_group_label": "Sham ExAblate Transcranial MRgFUS", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham treatment with ExAblate MR guided Focused Ultrasound"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a feasibility study to evaluate the safety and initial effectiveness of unilateral\n      ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from\n      medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate Transcranial\n      system compared to a Sham Vim thalamotomy procedure.\n\n      Data will be collected to establish the basic safety of this type of treatment as the basis\n      for later studies that will evaluate its full clinical efficacy. The Sham treatment data\n      will be used to evaluate placebo effect from treatment."
        }, 
        "brief_title": "ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "Subjects who sign informed consent and pass all eligibility criteria will be randomized to a\n      treatment assignment. During treatment, the assigned treatment (ExAblate Transcranial or\n      Sham ExAblate Transcranial)will be delivered. Subjects are followed in a blinded fashion for\n      three (3) months. After the 3-month assessment, subjects will be unblinded and told their\n      treatment assignment. Subjects receiving Sham ExAblate Transcranial treatment who still meet\n      criteria will be crossed over and receive an active ExAblate Transcranial treatment.\n      Subjects will be followed for up to two (2) years. Follow-up at 1 week, 1 month, 3 months, 6\n      months, 9 months, 12 months and up to two (2) years includes Unified Parkinson's Disease\n      Rating Scale (UPDRS) scoring, mental and cognitive functional testing and questionnaires."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women, age 30 years and older\n\n          -  Subjects who are able and willing to give informed consent and able to attend all\n             study visits\n\n          -  Subjects with a diagnosis of  idiopathic PD as confirmed from clinical history and\n             examination by a movement disorder neurologist at the site\n\n          -  Subject demonstrates a severe resting tremor or postural/action as measured by UPDRS\n\n          -  Subject exhibits a significant disability from their PD tremor despite medical\n             treatment\n\n          -  Subjects should be on a stable dose of all PD medications for 30 days prior to study\n             entry\n\n          -  Subject is able to communicate sensations during the ExAblate Transcranial procedure\n\n        Exclusion Criteria:\n\n          -  Subjects with unstable cardiac status\n\n          -  Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse\n\n          -  Severe hypertension\n\n          -  Subjects with standard contraindications for MR imaging such as non-MRI compatible\n             implanted metallic devices including cardiac pacemakers, size limitations, etc.\n\n          -  Known intolerance or allergies to the MRI contrast agent including advanced kidney\n             disease or severely impaired renal function\n\n          -  Significant claustrophobia that cannot be managed with mild medication\n\n          -  Current medical condition resulting in abnormal bleeding and/or coagulopathy\n\n          -  Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within\n             one week of focused ultrasound procedure or drugs known to increase risk or\n             hemorrhage\n\n          -  History of intracranial hemorrhage\n\n          -  History of multiple strokes,  or a stroke within past 6 months\n\n          -  Subjects who are not able or willing to tolerate the required prolonged stationary\n             supine position during treatment\n\n          -  Are participating or have participated in another clinical trial in the last 30 days\n\n          -  Subjects unable to communicate with the investigator and staff\n\n          -  Subjects with a history of seizures within the past year\n\n          -  Subjects with brain tumors\n\n          -  Subjects with intracranial aneurysms requiring treatment or arterial venous\n             malformations (AVMs) requiring treatment\n\n          -  Subjects who have had deep brain stimulation or a prior stereotactic ablation of the\n             basal ganglia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772693", 
            "org_study_id": "PD001"
        }, 
        "intervention": [
            {
                "arm_group_label": "ExAblate Transcranial MRgFUS", 
                "description": "ExAblate Transcranial MR Guided Focused Ultrasound", 
                "intervention_name": "ExAblate Transcranial MRgFUS", 
                "intervention_type": "Device", 
                "other_name": [
                    "ExAblate", 
                    "MRgFUS", 
                    "Focused Ultrasound", 
                    "Transcranial MRgFUS Thalamotomy"
                ]
            }, 
            {
                "arm_group_label": "Sham ExAblate Transcranial MRgFUS", 
                "description": "Sham ExAblate Transcranial MR Guided Focused Ultrasound", 
                "intervention_name": "Sham ExAblate Transcranial MRgFUS", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "ExAblate Transcranial MRgFUS", 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "FUSbrain@virginia.edu", 
                    "last_name": "Johanna Loomba", 
                    "phone": "434-243-1435"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University of Virginia"
                }, 
                "investigator": {
                    "last_name": "Jeff Elias, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Focusedultrasound@swedish.org", 
                    "last_name": "Colleen Ottinger", 
                    "phone": "206-320-3070"
                }, 
                "contact_backup": {
                    "email": "Focusedultrasound@swedish.org", 
                    "last_name": "Mary Lessig", 
                    "phone": "206-320-3070"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98122"
                    }, 
                    "name": "Swedish Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ryder Gwinn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease.", 
        "other_outcome": [
            {
                "description": "To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor dominant PD after the ExAblate treatment and during the follow-up period of up to 2 years.", 
                "measure": "Severity of Device and Procedure related complications", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor dominant PD after the ExAblate treatment and during the follow-up period of up to 2 years.", 
                "measure": "Incidence of Device and Procedure related complications", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor dominant PD after the ExAblate treatment and during the follow-up period of up to 2 years.", 
                "measure": "Incidence of Device and Procedure related complications", 
                "safety_issue": "Yes", 
                "time_frame": "At the time of the ExAblate Transcranial thalamotomy procedure"
            }
        ], 
        "overall_contact": {
            "email": "FUSbrain@virginia.edu", 
            "last_name": "Johanna Loomba", 
            "phone": "434-243-1435"
        }, 
        "overall_official": {
            "affiliation": "University of Virginia", 
            "last_name": "Jeff Elias, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor-dominant PD during the ExAblate treatment.", 
            "measure": "Severity of Device and Procedure related complications", 
            "safety_issue": "Yes", 
            "time_frame": "At the time of the ExAblate Transcranial thalamotomy procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772693"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the UPDRS score up to 3 months after ExAblate treatment.", 
            "measure": "UPDRS - Unified Parkinson's Disease Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "up to 3 months"
        }, 
        "source": "InSightec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InSightec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}